Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TLR3 | O15455 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | OGG1 | O15527 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BCKDK | O14874 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638757 | 1.00 | SENP1 (0.47) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL1638925 | 0.86 | SENP1 (0.48) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL1638927 | 0.86 | SENP1 (0.48) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL1638511 | 0.85 | MAPT (0.57) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL1638509 | 0.85 | MAPT (0.57) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL1637061 | 0.84 | SENP1 (0.47) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL1637059 | 0.84 | SENP1 (0.47) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL12726733 | 0.82 | HPGD (0.57) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL1637344 | 0.82 | HPGD (0.57) | SENP1MAPTSMN1; SMN2HPGDTLR3 | |
| SCHEMBL1637345 | 0.82 | HPGD (0.57) | SENP1MAPTSMN1; SMN2HPGDTLR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | claimed |
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009009768-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | APP, APBA1, BACE1 | SENP1 726/4885MAPT 85/4885SMN1; SMN2 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.